---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029611"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:13:31.372419+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated

## Summary
- Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).
- Reduced cortical/medullary tubular necrosis and neutrophilic inflammation at 0.35 mg/kg dose.
- Phase 1 clinical studies for Gemini initiated in February/March 2024.
- Data presented at the 29th Intl Conference on Advances in Critical Care Nephrology on March 12, 2024.
- Gemini is a synthetic TLR4 agonist that preconditions innate immunity to attenuate pro-inflammatory response.

## SEC filing metadata
- accession: 0000950170-24-029611
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/0000950170-24-029611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/revb-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029611
- JSON: https://secwatch.observer/filing/0000950170-24-029611.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.